Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 15/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 11/20 | 0.38 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.35 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5250106 | 0.96 | ACACB (0.38) | L3MBTL3L3MBTL1MBTD1CHRM1ACACB | |
| SCHEMBL3279563 | 0.96 | ACACB (0.38) | L3MBTL3L3MBTL1MBTD1CHRM1ACACB | |
| SCHEMBL3278543 | 0.88 | GAA (0.41) | L3MBTL3L3MBTL1CHRM1ACACBACACA | |
| SCHEMBL3285679 | 0.88 | L3MBTL3 (0.39) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL3282738 | 0.86 | KRAS (0.34) | ACACBACACA | |
| SCHEMBL3279106 | 0.85 | ITGB3 (0.39) | L3MBTL3L3MBTL1MBTD1GAAALOX12 | |
| SCHEMBL3285188 | 0.82 | CCR5 (0.41) | L3MBTL3L3MBTL1MBTD1ACACBACACA | |
| SCHEMBL3284870 | 0.82 | CCR5 (0.41) | L3MBTL3L3MBTL1MBTD1ACACBACACA | |
| SCHEMBL3279010 | 0.81 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1MBTD1CHRM1ACACB | |
| SCHEMBL3282544 | 0.81 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1MBTD1CHRM1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152171-A1 | CGRP Antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| US-7700589-B2 | CGRP antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-04-20 | — | — | US | disclosed |
| US-20070244099-A1 | CGRP Antagonists | RUDOLF KLAUS | 2007-10-18 | — | — | US | disclosed |
| EP-1558601-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-03 | — | — | EP | disclosed |
| US-20040132716-A1 | CGRP antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-08 | — | — | US | disclosed |
| WO-2004037811-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244099-A1 | CGRP Antagonists | CALCRL, OPRL1, CALCA | L3MBTL3 4478/4885L3MBTL1 3083/4885MBTD1 881/4885 |
| US-20100152171-A1 | CGRP Antagonists | CALCRL, OPRL1, CALCA | L3MBTL3 4478/4885L3MBTL1 3083/4885MBTD1 881/4885 |
| US-20040132716-A1 | CGRP antagonists | OPRL1, HTR1D, CALCA | L3MBTL3 4549/4885L3MBTL1 2373/4885MBTD1 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.